Pharmazz Revenue and Competitors
Estimated Revenue & Valuation
- Pharmazz's estimated annual revenue is currently $9.2M per year.
- Pharmazz's estimated revenue per employee is $201,000
Employee Data
- Pharmazz has 46 Employees.
- Pharmazz grew their employee count by -15% last year.
Pharmazz's People
Name | Title | Email/Phone |
---|---|---|
1 | Chief Operating Officer | Reveal Email/Phone |
2 | Project Manager | Reveal Email/Phone |
3 | Account Executive | Reveal Email/Phone |
Pharmazz Competitors & AlternativesAdd Company
Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
---|---|---|---|---|---|
#1 | $13.1M | 65 | 30% | N/A | N/A |
#2 | $75.6M | 376 | 7% | N/A | N/A |
#3 | $23.9M | 119 | 13% | $35M | N/A |
#4 | $12.7M | 63 | -3% | N/A | N/A |
#5 | $5.4M | 27 | -25% | N/A | N/A |
#6 | $6M | 30 | -35% | N/A | N/A |
#7 | $6.6M | 33 | -8% | N/A | N/A |
#8 | $13.5M | 67 | -3% | N/A | N/A |
#9 | $186.3M | 927 | 19% | N/A | N/A |
#10 | $4.4M | 22 | -4% | N/A | N/A |
What Is Pharmazz?
Pharmazz, Inc. is a clinical stage pharmaceutical company focused on discovering, acquiring, developing and commercializing therapeutics that target critical care medicine. The company is developing several clinical-stage product candidates, PMZ-2010 (Centhaquine), PMZ-1620 (Sovateltide) and PMZ-2123 for which it holds global marketing rights.
keywords:N/AN/A
Total Funding
46
Number of Employees
$9.2M
Revenue (est)
-15%
Employee Growth %
N/A
Valuation
N/A
Accelerator
Pharmazz News
2022-04-17 - Brain Edema Treatment Market Size, Share, Growth 2022 ...
Pharmazz Inc; Remedy Pharmaceuticals Inc. Brain Edema Treatment Market Breakdown by Type: PMZ-2123; FG-4497; Glyburide; Others.
2022-03-22 - Pharmazz Inc. announces FDA clearance of an IND ...
About Pharmazz, Inc. Pharmazz, Inc. is a privately held company engaged in developing novel products in critical care medicine. Additional...
Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
---|---|---|---|---|
#1 | $15.7M | 60 | 46% | N/A |
#2 | $23M | 135 | -4% | N/A |